Refinement of Clinician–Patient Risk Discussion e1123Ĩ.2.4. Improvement in Lifetime Risk Estimate e1123Ĩ.2.3. Economic Value Considerations: PCSK9 Inhibitors e1121Ĩ.2.1. Statin Safety and Statin-Associated Side Effects e1117ħ.1. Primary Prevention in Other Age Groups e1107ĥ. Monitoring in Response to LDL-C–Lowering Therapy e1106Ĥ.4.4. Primary Prevention Adults 40 to 75 Years of Age With LDL-C Levels 70 to 189 mg/dL (1.7 to 4.8 mmol/L) e1102Ĥ.4.3. Evaluation and Risk Assessment e1099Ĥ.4.2. Severe Hypercholesterolemia (LDL-C ≥190 mg/dL ) e1095Ĥ.4.1. Nonstatin Add-on Drugs to Statin Therapy e1091Ĥ.2. Lifestyle Therapies and Metabolic Syndrome e1090ģ.2.3. Diet Composition, Weight Control, and Physical Activity e1090ģ.1.2. Monitoring Response of LDL-C to Statin Therapy e1090ģ.1.1. Measurements of Apolipoprotein B and Lipoprotein (a) e1089Ģ.4. Measurements of LDL-C and Non–HDL-C e1088Ģ.3. Cholesterol, LDL-C, and ASCVD e1087Ģ.1.3. Cholesterol, Lipoproteins, and Apolipoprotein B e1087Ģ.1.2. Serum Cholesterol, Lipoproteins, and ASCVD e1087Ģ.1.1. High Blood Cholesterol and ASCVD e1087Ģ.1. Class of Recommendation and Level of Evidence e1087Ģ. Organization of the Writing Committee e1086ġ.5. Methodology and Evidence Review e1085ġ.2. Top 10 Take-Home Messages to Reduce Risk of Atherosclerotic Cardiovascular Disease Through Cholesterol Management e1083ġ.1. Customer Service and Ordering InformationĢ018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 kommentar(er)
